Ideal Cures has been granted a US patent for an immediate release film coating tech that - it claims - could rid the Pharma production sector of solvents.
Sourcing comparator drugs for trials is a complex ‘art’ that requires knowledge of trading, regional regulations and an awareness of drugmakers’ competitive concerns according to Clinigen Group CEO Peter George.
Bend Research has launched a formulation and production optimisation service for botherapeutics and vaccine makers, leveraging techs developed with Big Pharma partners.
Planning supply chains early is an important part of maintaining margins but is often overlooked by Pharmas too focused on developing the next product in an era of patent expiry says industry consultant.
Health Canada officials are working “around the clock” to approve 23 new drug applications in one month to combat national meds shortages caused by troubles at Sandoz.
GSK has made good on its promise to invest in the UK, confirming plans to spend £500m ($789m) on new manufacturing capacity in the country just a day after the Government introduced a tax ‘patent box.'
Another deal impacting the Pharma logistics space this week with rumoured former World Courier suitor UPS agreeing to stump up €5.2bn ($6.8bn) for Dutch rival TNT Express NV.
Synergy Health has completed a $62.9m (€47.6m) takeover of Swiss sterilisation firm Leoni Studer Hard from Leoni Group in a bid to further its reach in Europe.
Formac Pharmaceuticals and WR Grace say their silica platform can improve the formulation selection process for poorly soluble APIs (active pharmaceutical ingredients).
Indian API manufacturers may dominate the list of companies that have had CEPs suspended this year, but that may say more about inspection policies than it does about standards outside Europe.
Generic API (active pharmaceutical ingredient) makers should consider the off-patent potential of a drug as soon as it is launched, according to a new study by PharmaIntellect.
inVentiv Health will stump up $50m for contract staffing firm Kforce Clinical Research (KCR) to ramp up its funcatiuonal service provider (FSP) business.
More bad news for troubled CMO Ben Venue Laboratories after European regulators recommend that production of two more drugs – Caelyx and Ceplene – is relocated to other facilities.
The European CMO sector is set to double in the next six years and will hit revenues of up to $20.75bn, according to Frost & Sullivan’s Aiswariya Chidambaram.
Two major ferry companies have decided to stop shipping animals used in preclinical drug development to the UK, prompting concerns about the future of the country’s research sector.
Quintiles has inked a deal with Delcath which will see it deploy a team of medical experts to support the European launch of the Hepatic Chemosat Delivery system.
Generics and API maker Ranbaxy has opened a plant in Casablanca, Morocco in a bid to strengthen its foothold in the “increasingly important” North African drugs market.